B and T cells constitute the majority of infiltrating lymphocytes in the kidney and represent the local perpetrators of lupus nephritis (LN). Previous studies have found the enrichment ... mTORC1, ...

Panelists discuss the updated treatment recommendations for lupus nephritis in the Kidney Disease Improving Global Outcomes and European Alliance of Associations for Rheumatology guidelines ...

Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for ...

Since June 2023, I have been running the 4-factor stock screener on a monthly basis and tracking the list of top-ranked stocks. I want to accumulate this data to run additional tests on more ...

Complement factor I and complement factor H can limit the activity of C3 convertase and bind to C3b, preventing novel convertase formation (40). In a variety of diseases, complement system activation ...

The Citroen C3 now offers an automatic gearbox option, introduced over two years after its launch in India. This new feature is available only in the top-spec Shine variant, with prices ranging ...

This suggests that serial monitoring of serum CD44 level may serve as an early indicator of impending nephritic flare. Immunological activity in LN is characterized by an increase in anti-dsDNA ...

The updated Citroen C3 gets a 6-speed torque converter paired with the 1.2-litre turbo petrol engine. This is the same unit that is available on the C3 Aircross and the recently launched Basalt Coupe ...

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis.

Great Britain's Sophie Unwin and Jenny Holl won silver in the women's B road race at the UCI Road and Para-cycling Road World Championships in Zurich. Fresh from claiming two gold medals at the ...

Oracle’s cloud growth is being driven by AI tailwinds. C3.ai hasn’t proven its business model is sustainable yet. The blue chip stalwart could continue to outperform the higher-growth challenger.

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN). Gazyva is an engineered humanized monoclonal antibody ...